Repatha Injection: Dosing, Devices, and What to Expect at Home
Two Dosing Schedules, Same LDL Reduction
Repatha is available in two dosing schedules: 140 mg every two weeks or 420 mg once monthly. The biweekly dose is a single injection, while the monthly dose involves three injections within a 30-minute window. In clinical studies of patients on statin therapy, both schedules produced LDL-C reductions from baseline of approximately 65 percent, with similar results regardless of which schedule was used (PMID 27066336). Patients can switch between the two schedules at any scheduled dose based on personal preference.
Device Options: Autoinjector, Syringe, or Mini-Doser
The biweekly dose can be delivered using either a prefilled autoinjector pen or a prefilled syringe. The monthly dose can be given with three autoinjectors, three syringes, or a single automated mini-doser. Research across multiple injectable biologics demonstrates that autoinjectors and prefilled syringes produce equivalent drug absorption. In one study of galcanezumab, the 90% confidence interval for the ratio of drug concentrations between devices fell within the standard 0.80 to 1.25 bioequivalence range (PMID 30271122). Similar bioequivalence has been confirmed for ofatumumab, where autoinjector and syringe delivery produced virtually identical exposure (ratio 1.03 for AUC, 1.00 for peak concentration; PMID 34605319).
Where and How to Inject
Repatha is injected subcutaneously, meaning under the skin rather than into muscle. According to the prescribing information, approved injection sites include the abdomen, front of the thigh, and outer upper arm. The outer arm site requires a caregiver to administer. Patients should rotate injection sites between doses to minimize local irritation. Each autoinjector and syringe is single-use and should be disposed of in an FDA-cleared sharps container.
Training in the Clinic, Then Self-Administering at Home
In clinical studies, the first self-administration occurred in a clinic setting under healthcare provider supervision. Once patients or caregivers demonstrated they could use the device correctly, subsequent injections moved to the home setting. Across two studies enrolling a combined 313 patients (149 in the biweekly study, 164 in the monthly study), approximately 95 percent of at-home self-administrations were completed successfully (PMID 27066336). Rates of successful self-administration were similar regardless of which device or dosing schedule patients used.
Storage and Preparation
According to the prescribing information, Repatha should be stored in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Before injecting, let the device sit at room temperature for at least 30 minutes. Do not heat or microwave it. Inspect the solution through the viewing window: it should be clear to slightly yellow with no visible particles. If the solution appears discolored or contains particulates, do not use it.
Incomplete Dosing: What the Data Shows
A 2024 analysis of FDA postmarketing reports found that incomplete dosing events occur with PCSK9 inhibitor self-injectors. For evolocumab specifically, the proportional reporting ratio for patient usage complications was 3.44 (95% CI 3.38 to 3.50), indicating these events were reported at a higher rate than for comparable self-injected medications (PMID 38874875). Confirming the viewing window shows the dose was fully delivered and following the device instructions carefully can help reduce this risk.
Side Effects and What to Expect
In the clinical studies of home self-administration, adverse events were similar between device groups and generally mild in severity (PMID 27066336). Injection site reactions are the most commonly reported local effect. Serious allergic reactions are rare but possible. If you experience hives, swelling of the face or throat, or difficulty breathing after injection, contact your prescribing physician immediately.